Carrier Biomed

Carrier Bio is a clinical-stage biotechnology company focused on developing next-generation therapies for metabolic diseases, including obesity, type 2 diabetes, and NASH. The company's core strength lies in its proprietary Carrier-mediated PROdrug (C-PRO) platform, which facilitates the oral administration of peptides and enhances the delivery of small molecules. Carrier Bio's pipeline features several potent multi-agonists, such as CB01 (GLP-1) and CB03 (GLP-1/GIP), designed to offer superior efficacy and patient compliance. Headquartered in Beijing with operations in the United States, the company is backed by prominent life science investors. Its technology aims to transform the treatment landscape by providing oral alternatives to injectable biologics.